Latest clinical research confirms that IQOS reduces smoker exposure to select harmful chemicals as compared to cigarette smoke

Studies conducted to date clearly indicate that IQOS is likely to present less risk of harm compared to smoking

LAUSANNE, Switzerland, March 28 (BUSINESS WIRE)-- Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today announces the positive results from an advanced clinical study on IQOS, the company’s first electronically heated tobacco product, published in the peer-reviewed journal Nicotine & Tobacco Research.

Conducted in Japan over a three-month period by the well-known clinical research organization, the Osaki Hospital Tokyo Heart Center, the study showed that smokers who switched to IQOS:

• Reduced their exposure to 15 harmful chemicals to levels that approached those of smokers who quit smoking;
• Showed improvements in measured health indicators specific to smoking-related diseases, such as lung and heart disease. In all cases, the health indicators improved in the same direction as seen in smokers who quit. Further testing through a longer-term study is underway; and
• Found the product satisfying and were likely to completely switch to it.

Source: Philip Morris International